Nykode Therapeutics AS (NYKD.OL)
NOK 3.19
(-4.61%)
NOK 3.19
(-4.61%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -926.83 Million | -163.96 Million | 11.71 Million | 1.69 Billion | -92.19 Million | -62.78 Million |
| Net Income | -371.59 Million | -411.21 Million | -80.94 Million | 1.4 Billion | -120.55 Million | -63.79 Million |
| Depreciation & Amortization | 22.43 Million | 17.44 Million | 6.32 Million | 2.86 Million | 1.4 Million | 58 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 3.7 Million | 3.83 Million | 3.44 Million | 2.59 Million | - | - |
| Change in working capital | -474.42 Million | 249.25 Million | 68.88 Million | -50.5 Million | 24.4 Million | 952 Thousand |
| Other non-cash items | -54.6 Million | -217.88 Million | 226.8 Million | 312.48 Million | -1.36 Million | 2.02 Million |
| Investing Cash Flow | -20.1 Million | 70.87 Million | 90.13 Million | -56.72 Million | -80.09 Million | -79 Thousand |
| Investments in PPE | -20.1 Million | -25.73 Million | -7.49 Million | -931.93 Thousand | -668.97 Thousand | -79 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -8.58 Million | -142.2 Million | -104.8 Million | - |
| Sales/Maturities of investments | - | 96.61 Million | 106.22 Million | 86.4 Million | 25.38 Million | - |
| Other Investing Activities | 8.94 Million | - | 1000.00 | -1000.00 | - | - |
| Financing Cash Flow | 471.32 Million | 3.78 Million | 176.32 Million | -2.38 Million | 227.9 Million | 337 Thousand |
| Debt repayment | -893 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 483.03 Million | 17.28 Million | 182.14 Million | - | 229.29 Million | 337 Thousand |
| Other Financing Activities | -1.1 Million | - | -1000.00 | 1000.00 | 1000.00 | - |
| Accounts receivables | 25.51 Million | 211.38 Million | -191.05 Million | -36.81 Million | -3.24 Million | -1.34 Million |
| Accounts payables | -29.3 Million | 21.94 Million | -5.64 Million | 64.44 Million | 9.97 Million | -564 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -470.63 Million | 15.92 Million | 265.58 Million | -78.13 Million | 17.68 Million | 2.86 Million |
| Cash at beginning of period | 2.03 Billion | 1.9 Billion | 1.57 Billion | 89.32 Million | 32.44 Million | 40.27 Million |
| Cash at end of period | 1.65 Billion | 2.03 Billion | 1.9 Billion | 1.57 Billion | 89.32 Million | 32.44 Million |
| Capital Expenditure | -20.1 Million | -25.73 Million | -7.49 Million | -931.93 Thousand | -668.97 Thousand | -79 Thousand |
| Effect of forex changes on cash | 1.21 Million | -560 Thousand | 30 Thousand | -272 Thousand | - | - |
| Net cash flow / Change in cash | -381.77 Million | 126.31 Million | 332.66 Million | 1.48 Billion | 56.88 Million | -7.83 Million |
| Free Cash Flow | -946.94 Million | -189.7 Million | 4.21 Million | 1.69 Billion | -92.86 Million | -62.86 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.48 Million | -157.22 Million | -57.83 Million | -371.59 Million | -107.38 Million | -98.71 Million |
| Depreciation & Amortization | 567 Thousand | 5.99 Million | 6.15 Million | 22.43 Million | 5.73 Million | 5.8 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 745 Thousand | 2.4 Million | 1.47 Million | 3.7 Million | 809 Thousand | 646 Thousand |
| Change in working capital | -3.77 Million | -12.83 Million | -326.14 Million | -474.42 Million | -24.18 Million | -54.7 Million |
| Other non-cash items | -1.17 Million | 48.89 Million | -78.39 Million | -54.6 Million | -410.3 Thousand | 8 Million |
| Investing Cash Flow | 2.52 Million | -126.25 Thousand | -2 Million | -20.1 Million | -9.34 Million | -1.66 Million |
| Investments in PPE | -7000.00 | -126.25 Thousand | -2 Million | -20.1 Million | -9.34 Million | -1.66 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 2.52 Million | - | - | - | - | - |
| Financing Cash Flow | -296 Thousand | -3.26 Million | 471.38 Million | 471.32 Million | -3.15 Million | -2.48 Million |
| Debt repayment | -249 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 474.4 Million | 483.03 Million | -48.44 Thousand | 194.51 Thousand |
| Other Financing Activities | -296 Thousand | - | - | - | - | - |
| Accounts receivables | -850 Thousand | 4.59 Million | 12.41 Million | 25.51 Million | 31.27 Thousand | 26.42 Million |
| Accounts payables | - | -23.23 Million | 1.34 Million | -29.3 Million | 455.03 Thousand | -5.04 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.92 Million | 5.79 Million | -339.9 Million | -470.63 Million | -24.67 Million | -76.08 Million |
| Cash at beginning of period | 147.29 Million | 1.65 Billion | 1.69 Billion | 2.03 Billion | 1.85 Billion | 1.94 Billion |
| Cash at end of period | 136.53 Million | 1.59 Billion | 1.65 Billion | 1.65 Billion | 1.69 Billion | 1.85 Billion |
| Capital Expenditure | -7000.00 | -126.25 Thousand | -2 Million | -20.1 Million | -9.34 Million | -1.66 Million |
| Effect of forex changes on cash | 137 Thousand | -1.12 Million | 1.43 Million | 1.21 Million | 95 Thousand | -248 Thousand |
| Net cash flow / Change in cash | -10.76 Million | -53.38 Million | -41.96 Million | -381.77 Million | -166.39 Million | -90.01 Million |
| Free Cash Flow | -13.13 Million | -145.92 Million | -456.78 Million | -946.94 Million | -146.57 Million | -131.5 Million |
UNIF
1271
HRAL
VINYOFL
4FY
7093